Skyrizi was the top Rx and over-the-counter (OTC) pharma brand advertising on TV in 2024, according to data released by iSpot.tv on Thursday afternoon. AbbVie’s psoriasis, ulcerative colitis, Crohn’s ...
After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...
StockStory.org on MSN
The Top 5 Analyst Questions From AbbVie’s Q3 Earnings Call
AbbVie’s third quarter results were marked by strong year-on-year revenue growth, driven primarily by continued momentum in ...
Oct 30 (Reuters) - AbbVie (ABBV.N), opens new tab raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street ...
For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion. | ...
AbbVie raised its 2025 profit forecast on Friday, after strong sales of newer immunology drugs Skyrizi and Rinvoq helped ...
CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with $56.3 billion in total net revenues for the year, up 4.6% operationally, despite $5 billion in U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback